My take on how 2-drug regimens and investigational agents are expanding our options for successful antiretroviral therapy in treatment-naive patients, virally suppressed patients switching regimens, and potentially to patients experiencing virologic failure.
Thoughts on how investigational, long-acting 2-drug regimens involving drugs with novel mechanisms of action may expand treatment options not only for treatment-experienced patients, but also for ART-naive patients in key populations with specific needs.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.